Home
Company
News & events
5th Annual STING & TLR-Targeted Therapies Summit, San Diego, CA, June 19-20, 2024

5th Annual STING & TLR-Targeted Therapies Summit, San Diego, CA, June 19-20, 2024

Conference

genOway presentation

Event
-
June 19, 2024

June 19-20, 2024

Advancing the Next Wave of Immunotherapeutics: STING, TLR & Beyond

‍

‍

genOway's presentation on June 19, 2024 | 1 p.m. PDT:

Profiling STING and TLR-Targeted Therapies in Preclinical Models

  • Focus on STING humanized mouse models and BRGSF-HIS, hCD34+ reconstituted mice featuring human lymphoid and myeloid compartments
  • Characterization of the immune responses
  • Showcase of assessment of STING and TLR-targeting agents in these models

‍

▶ Get more information on the STING & TLR-Targeted Therapies Summit 2024 here

5th Annual STING & TLR-Targeted Therapies Summit, San Diego, CA, June 19-20, 2024

Get in touch about

Let us know how we can help

In order to provide you the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please tick the checkbox below.

From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Other news & events

genOway Shanghai at the Chinese Biopharmaceutical Association meeting 2024
Conference
Event
-
Jul 2024
Read on
5th Annual STING & TLR-Targeted Therapies Summit, San Diego, CA, June 19-20, 2024
Conference
genOway presentation
Event
-
Jun 2024
Read on
Another technological achievement for genOway's humanized ICP (immune checkpoint) models, used successfully by Curadev Pharma in the preclinical trials of its drug candidate CRD3874 for the treatment of advanced/metastatic solid cancers
2023
IND (Investigational New Drug)
News
-
Aug 2023
Read on
Sigma-Aldrich and genOway expand their CRISPR/Cas9 strategic alliance
2022
Intellectual property
News
-
Sep 2022
Read on
genOway grants the leading UK academic research funder a non-exclusive license for CRISPR/Cas9 technology
2022
Intellectual property
News
-
Jan 2022
Read on